Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma
This study is a open-lable , single armï¼Œsingle center, phase II clinical study. Target population is patients with high-risk Soft tissue sarcoma. Study objective is to compare the efficacy and safety of camrelizumab in combination with Liposome doxorubicin and Ifosfamide in study population in China. Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.
Soft Tissue Sarcoma
DRUG: Camrelizumab in Combination With Neoadjuvant Chemotherapy
Objective response rate, ORR, 24 months
2 years Overall Survival (OS) rate, The percentage of patients overall survival in 2 years, 24 months|2 years Progression-free survival (PFS) rate, The percentage of patients Progression-free survival in 2 years, 24 months|Adverse Events (AEs), All adverse event/Serious adverse event that occurred during the study period according to CTCAE, 24 months
In this study, eligible subject will be enrolled into study arm to accept study treatment. Treatment cycles of chemotherapy will be at most 8 cycles which will be decided by investigators. Objective response rate will be the primary outcome measures.